PARI Asia Pacific Ltd.

PARI Asia Pacific Ltd. Established: 13 June 2018 Headquarters: Central, Hong Kong Parent Company: PARI Medical Holding GmbH, Germany (www.pari.com) Company Overview: PARI Asia Pacific Ltd. is the regional subsidiary of PARI Medical Holding GmbH, a global leader in respiratory therapy solutions. Since its establishment in 2018, PARI Asia Pacific has been committed to improving respiratory health across China, Japan, Southeast Asia, and Australia by delivering innovative, scientifically proven inhalation devices and aerosol therapy systems. Core Products: • PARI BOY® Series – trusted nebulizer systems for effective inhalation therapy • eFlow® rapid – advanced vibrating membrane nebulizer for efficient aerosol delivery • PARI LC SPRINT® – high-performance jet nebulizer technology • VORTEX® – antistatic holding chamber for metered-dose inhalers Unique Differentiators: • Proven product efficiency supported by numerous clinical studies • Strategic collaborations with pharmaceutical companies for new drug development Vision Statement: At PARI, we are passionate about working for a world where everyone can breathe freely. We pursue this path by developing innovative, high-quality, and scientifically proven products for the treatment of respiratory diseases — for our patients and customers, for our employees, for the environment and society. Locally and globally.